SCHEMBL5405033

SCHEMBL5405033

COc1cc(SC)ccc1C(=O)N1CCC2(CCN(Cc3ccccc3OCc3ccccc3)CC2)CC1

nearest known ligand 0.65

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.65
CYP2D6 P10635 9/20 0.56
ALDH1A1 P00352 1/20 0.56
CHRM2 P08172 1/20 0.54
CHRM3 P20309 1/20 0.54
TSHR P16473 3/20 0.53
USP2 O75604 3/20 0.53
CYP3A4 P08684 2/20 0.53
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.51
LMNA P02545 1/20 0.51
HPGD P15428 1/20 0.51
CCR8 P51685 5/20 0.51
KCNH2 Q12809 5/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL5433995 0.96 GAA (0.60) GAACYP2D6ALDH1A1CHRM2CHRM3
SCHEMBL5402137 0.91 GAA (0.60) GAACYP2D6ALDH1A1CHRM2CHRM3
SCHEMBL5428641 0.88 CCR8 (0.60) CYP2D6ALDH1A1CHRM2CHRM3TSHR
Trifluoroacetic Acid SCHEMBL5446287 0.88 GAA (0.57) GAACYP2D6ALDH1A1CHRM2CHRM3
SCHEMBL5434000 0.86 GAA (0.52) GAACYP2D6ALDH1A1CHRM2CHRM3
Trifluoroacetic Acid SCHEMBL5432761 0.84 CCR8 (0.56) CYP2D6ALDH1A1CHRM2CHRM3TSHR
SCHEMBL5409231 0.83 CCR8 (0.56) GAACYP2D6ALDH1A1TSHRUSP2
SCHEMBL5397436 0.83 CYP2D6 (0.60) GAACYP2D6ALDH1A1CHRM2CHRM3
SCHEMBL5402950 0.81 CYP2D6 (0.65) CYP2D6ALDH1A1TSHRUSP2CYP3A4
Trifluoroacetic Acid SCHEMBL5446116 0.81 CCR8 (0.52) GAACYP2D6ALDH1A1TSHRUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249648-A1 Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases ASTRAZENECA AB (SE) 2007-10-25 US claimed
JP-2007509141-A 2007-04-12 JP claimed
EP-1678178-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES AstraZeneca AB (SE) 2006-07-12 EP claimed
WO-2005040167-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES ASTRAZENECA AB (SE) 2005-05-06 WO claimed
US-20070249648-A1 Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases ASTRAZENECA AB (SE) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249648-A1 Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases CCR8, CCR1, CCR10 GAA 2459/4885CYP2D6 1764/4885ALDH1A1 1230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.